Phil Ferneau | Borealis Ventures

Phil is a co-founder and managing director of Borealis Ventures, a US-based early-stage venture capital firm. Phil directs the firm's healthcare investing, focusing on life science and digital health opportunities, often based on commercializing technology arising from academic research.

He currently leads Borealis’ investments in Adimab, Avedro, Avitide, Compass Therapeutics, Orbit Discovery, and Vets First Choice. Phil was also responsible for the firm’s prior investments in GlycoFi (acquired by Merck & Co.) and M2S (acquired by AIG Altaris Health Partners).

Phil previously served as the founding Executive Director of the Center for Private Equity and Entrepreneurship at Dartmouth College’s Tuck School of Business. Phil remains an adjunct member of Tuck’s faculty teaching graduate courses in venture capital and entrepreneurship.

Earlier in private legal practice in Washington, DC, he counseled technology startups, Fortune 500 companies and foreign governments on sensitive trade, tax, and investment matters. Phil received an A.B. degree from Dartmouth College, a J.D. from the University of Virginia School of Law, and a M.B.A. from the Tuck School of Business at Dartmouth (Tuck Scholar with High Distinction).
Close Menu